Medicure Reports Strong Q1 Revenue Growth, Reduced Net Loss, and Improved EBITDA
MCUJF sits 84% above its 52-week low of $0.436.
Summary
Medicure reported Q1 2026 results with total net revenue increasing to $7.9 million from $5.4 million year-over-year. The company significantly reduced its net loss to $406,000 ($0.04/share) from $694,000 ($0.07/share) and saw adjusted EBITDA jump to $280,000 from $28,000. This positive Q1 performance follows a 20-F filing in April that reported a substantial increase in net loss and a dramatic decline in cash for the prior fiscal year. The improved Q1 results suggest a potential turnaround from those negative trends, driven by growth in ZYPITAMAG and the pharmacy segment, despite a decline in AGGRASTAT sales due to generic competition. The company has scheduled a conference call for May 25, 2026, which may provide further details and outlook.
At the time of this announcement, MCUJF was trading at $0.80 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.44 to $1.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.